DOCSLIB.ORG

Androgen Receptor Expression on Granulosa Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Androgen Receptor Expression on Granulosa Cells Intracellular pathways: from stimula to final effects Claus Yding Andersen, MSc, DMSc Professor Laboratory of Reproductive Biology University Hospital Copenhagen, University of Copenhagen, Copenhagen, Denmark E-mail: [email protected] ”ART: Experimental bases for improving outcomes for the benefit of patients” SERONO SYMPOSIA, February 19-20, 2010 Istanbul, Turkey In order to increase the efficacy of ovarian stimulation and possibly enhance outcome of infertility treatment one approach is to understand the starting point better: the human small antral follicle and ask whether it is possible to improve follicular heath and FSH sensitivity prior to the application of supra physiological FSH levels Content Gonadotropins: mode of action Effect of androgens on follicles Human small antral follicles: characterization Androgen Receptor and FSHR expression Clinical trial to study androgen priming ”ART: Experimental bases for improving outcomes for the benefit of patients” SERONO SYMPOSIA, February 19-20, 2010 Istanbul, Turkey Classification of follicles in the human ovary Gougeon A. Endocr Rev. 1996;17:121. FSH and LH interacts with its receptor on the theca and 4/20/2009 Claus Ydinggranulosa Andersen, MSc, DMSc: Molecular cells Action of LH on the Follicle 5 Signalling pathways activated by the FSHR and the LHR Extracelluar activation of the receptor leads to intracellular activation of : Adenylyl cyclase cAMP pathway PKC inositol phosphate pathway MAPK cascade FSHR govern the induction of LHR formation, but the control of FSHR formation is not well characterized but at what follicular stage LHR expressed on granulsa cells Effect of FSH and LH on steroidogenesis Granulosa cells Theca cells LH Oestradiol FSH Androgens LH Androgen has a dual role in folliculogenesis During the early stage of follicular development androgens acts as an enhancer of FSH-stimulated follicular differentiation Androgens inhibit later stages of follicular development Serve as substrate for oestrogen production Tetsuka M & Hillier SG, J Steroid Biochem Molec Biol, 1997, 61, 233 Androgens augments follicular FSH receptor expression in primate ovaries Weil S et al., JCEM, 2951, 84, 1999 Androgen Receptor gene expression in the primate ovary Weil S et al., JCEM, 1998, 83, 2479 Androgens augments follicular FSH receptor expression in primate ovaries Weil S et al., JCEM, 2951, 84, 1999 Small antralHalf follicles a human ovary Corpus Luteum Follicles Corpus luteum Human ovaries for cryopreservation Collection of follicular fluid and granulosa cells of small human antral follicles Analysis mRNA expression in GC and measurement of follicular fluid hormones in a total of 64 follicles randomly collected mRNA results from a total of 55 follicles Follicular fluids collected in a total of 24 women: Number of follicles per women Number of patients 1 5 2 8 3 7 4 2 6 1 8 1 Does Androgen Receptor expression and testosterone levels in the follicle correlate with the FSH-receptor expression in naive human small antral follicles? mRNA levels measured in the granulosa cells: AR, FSHR, LHR, CYP19a1, AMHR2 Hormones measured in the follicular fluid: AMH, Inhibin-B, oestradiol, progesterone, testosterone and androstenedione Western Blot and immunohistochemistry of the Androgen Receptor Gene Expression in Human Granulosa Cells from Follicles 3 -9 mM in Diameter in Relation to the Hormonal Profiles of the Associated Follicle Fluids Androgen Receptor mRNA expression (x1000) (Mean SEM) < 20 20 – 45 > 45 –130 > 130 Spearman Number 11 16 14 14 FSH-R (x1000) 18 8 56 13 133 31 181 49 P <0.0001 LH-R (x1000) 0,63 0,27 0,53 0,19 0,87 0,22 1,76 0,69 P <0.02 AMHR-2 (x1000) 4,6 1,4 21,2 7,8 16,2 3,8 23,2 3,1 P <0.0008 CYP-19 (x1000) 38 21 33 16 19 7 48 15 P >0.10 No significant relation to Follicular Fluid hormone parameters AMH, Inhibin-B, Oestradiol, Progesterone, Androstenedione and Testosterone 4/20/2009 Claus Yding Andersen, MSc, DMSc: Molecular Action of LH on the Follicle 16 Correlation between FSHR and AR mRNA expression levels F S H r m R N A e x p re s s io n (X 1 0 0 0 ) 1000 100 10 1 1 Androgen Receptor mRNA expression (X1000) 10 100 1000 AMH-receptor2 expression Correlation between FSHR and AMHr2 mRNA 100 10 1 1 FSH-receptor mRNA expression expression levels 10 100 1000 Follicular fluid concentrations of testosterone in relation to mRNA expression of gonadotropin receptors, CYP19 and AMH-r2 genes in the corresponding granulosa cells Testosterone concentration (nmol/L) (Mean SEM) < 145 146 – 210 211 - 350 >350 Spearman Number 15 13 13 13 FSH-R (x1000) 52 17 49 16 122 35 185 51 P < 0.003 LH-R (x1000) 1,0 0,3 0,7 0,2 1,2 0,6 0,8 0,3 P >0.10 AMHR-2 (x1000) 10 2 25 10 17 4 20 5 P >0.10 CYP-19 (x1000) 38 16 46 22 36 13 19 9 P >0.10 Significant relation to Follicular Fluid inhibin-B and androstenedione concentrations, whereas the other hormone parameters including AMH, Oestradiol and Progesterone did not correlate. 4/20/2009 Claus Yding Andersen, MSc, DMSc: Molecular Action of LH on the Follicle 19 Gene Expression in Human Granulosa Cells from Follicles 3- 9 mM in Diameter in Relation to the Hormonal Profiles of the Associated Follicle Fluids LH-receptor (x1000) (Mean SEM) 0.12 0.12 – 0.25 0.25 – 1.0 > 1.0 Spearman Number 18 12 11 14 FSH-R (x1000) 62 16 59 19 100 21 182 52 P <0.05 Progesterone(nM) 246 32 308 75 435 99 576 112 P <0.05 Oestradiol (nM) 158 75 120 82 102 50 418 260 P >0.10 CYP-19 (x1000) 12 6 34 21 33 17 123 67 P >0.10 No significant relation to AMH-FF, AMH-R2, AR and FF testosterone 4/20/2009 Claus Yding Andersen, MSc, DMSc: Molecular Action of LH on the Follicle 20 Human small antral follicles are characterized by Confirming results from primates Androgen Receptor expression on granulosa cells A significant correlation between mRNA levels of AR and FSHR A significant correlation between FF-testosterone and FSHR expression mRNA levels of FSHR is significantly correlated to those of LHR PCO women are sensitive to FSH stimulation They often hyper-respond to exogenous FSH stimulation Granulosa cells are hyper-responsive to FSH in vitro They use less exogenous FSH and less FSH per oocyte retrieved PCO women are characterized by Enhanced LH activity Enhanced androgen action Without the action of FSH Could some of the mechanisms that make PCO women sensitive to FSH stimulation be used to enhance follicular sensitivity in low or moderate responder patients? Aim: Temporary reversible PCO-like condition prior to ovarian stimulation Androgen Priming: Clinical study Prospective, Non-randomized Pilot Study 45 patients with 15 in each of 3 different groups Inclusion criteria – IVF/ICSI treatment – age between 20 and 40 – regular menstrual cycle – BMI between 18 and 30 kg/m² – FSH and LH < 12 IU/l cd 2-3 Stimulation protocol – Androgen priming hCG, 1250 IE Aromatase inhibitor, letrozole 2,5 mg daily Group 3 Group 2 GnRH antagonist, cetrorelix 3 mg Group 1 menotropin 150/225 Individual dose Downregulation and priming Flexible antagonist protocol cd2 cd5 cd8 cd14 stim.1 stim.7 Løssl K et al., Hum Reprod. 21, 2593, 2006 Androgen priming using aromatase inhibitor and hCG during early follicular phase GnRH antagonist down-reguglation in modified antagonist protocols Baseline Characteristics Group 2 Group 3 Group 1 P value + AI + AI + hCG No. patient 15 15 15 Age (mean) 32,4 ± 1 32,6 ± 1 32,8 ± 1 NS IVF/ICSI (n) 5/10 5/10 5/10 Earlier treatments (n) 0,7 ± 0,3 0,9 ± 0,3 0,8 ± 0,3 NS Pretreatment FSH, LH, oestradiol and testosterone levels similar between groups Løssl K et al., Hum Reprod. 21, 2593, 2006 4/20/2009 Claus Yding Andersen, MSc, DMSc: Molecular Action of LH on the Follicle 27 Androgen priming using aromatase inhibitor and hCG during early follicular phase GnRH antagonist down-reguglation in modified antagonist protocols Outcome of stimulation Group 2 Group 3 Group 1 P value + AI + AI + hCG Days of stimulation 9,4 9,6 10,3 NS Total FSH dose (IE) 2030 1917 2110 NS Endometrium (mm) 9,9 9,1 8,5 NS Follicles (>12 mm) 6,1 ± 0,7 9,5 ± 1,5 8,4 ± 1,3 NS Equal number of follicles on stimulation day 1 Løssl K et al., Hum Reprod. 21, 2593, 2006 4/20/2009 Claus Yding Andersen, MSc, DMSc: Molecular Action of LH on the Follicle 28 Androgen priming using aromatase inhibitor and hCG during early follicular phase GnRH antagonist down-regulation in modified antagonist protocols Outcome of IVF stimulation Group 2 Group 3 Group 1 P value + AI + AI + hCG Aspirations (n) 13 15 13 Oocytes (n) 5,7 ±0,6 8,4 ±1,2 8,4 ±1,1 NS Fertilizationrate 61 ± 6,1 40 ± 5,2* 60 ± 7,4 *P=0,03 Embryos (n) 3,1 ±0,4 2,7 ±0,6 5,2 ±0,7* *P=0,01 Cryopreserved 1,0 ±0,5 1,0 ±0,5 2,6 ±0,7 NS embryos (n) Løssl K et al., Hum Reprod. 21, 2593, 2006 4/20/2009 Claus Yding Andersen, MSc, DMSc: Molecular Action of LH on the Follicle 29 Androgen priming using aromatase inhibitor and hCG during early follicular phase GnRH antagonist down-regulation in modified antagonist protocols Reproductive Outcome Group 2 Group 3 Group 1 P value + AI + AI + hCG Cycles 15 15 15 NS Pos. hCG 47% 40% 47% NS Implantation rate 39 % 20% 26% NS Ongoing/cycle 27 % 27% 33% NS Ongoing/transfer 33 % 31% 42% NS Løssl K et al., Hum Reprod.
Load more

Recommended publications
  • Gonadotropin Therapy in Assisted Reproduction: an Evolutionary Perspective from Biologics to Biotech
    REVIEW Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech Roge´rio de Barros F. Lea˜ o, Sandro C. Esteves Andrology & Human Reproduction Clinic (ANDROFERT), Referral Center for Male Reproduction, Campinas/SP, Brazil. Gonadotropin therapy plays an integral role in ovarian stimulation for infertility treatments. Efforts have been made over the last century to improve gonadotropin preparations. Undoubtedly, current gonadotropins have better quality and safety profiles as well as clinical efficacy than earlier ones. A major achievement has been introducing recombinant technology in the manufacturing processes for follicle-stimulating hormone, luteinizing hormone, and human chorionic gonadotropin. Recombinant gonadotropins are purer than urine- derived gonadotropins, and incorporating vial filling by mass virtually eliminated batch-to-batch variations and enabled accurate dosing. Recombinant and fill-by-mass technologies have been the driving forces for launching of prefilled pen devices for more patient-friendly ovarian stimulation. The most recent developments include the fixed combination of follitropin alfa + lutropin alfa, long-acting FSH gonadotropin, and a new family of prefilled pen injector devices for administration of recombinant gonadotropins. The next step would be the production of orally bioactive molecules with selective follicle-stimulating hormone and luteinizing hormone activity. KEYWORDS: Gonadotropins; Ovulation Induction; Assisted Reproductive Techniques; Systematic Review.
    [Show full text]
  • Aromatase Inhibition Reduces the Dose of Gonadotropin Required for Controlled Ovarian Hyperstimulation Mohamed F
    Journal of the Society for Gynecologic Investigation http://rsx.sagepub.com Aromatase Inhibition Reduces the Dose of Gonadotropin Required for Controlled Ovarian Hyperstimulation Mohamed F. M. Mitwally and Robert F. Casper Journal of the Society for Gynecologic Investigation 2004; 11; 406 DOI: 10.1016/j.jsgi.2004.03.006 The online version of this article can be found at: http://rsx.sagepub.com/cgi/content/abstract/11/6/406 Published by: http://www.sagepublications.com On behalf of: Society for Gynecologic Investigation Additional services and information for Journal of the Society for Gynecologic Investigation can be found at: Email Alerts: http://rsx.sagepub.com/cgi/alerts Subscriptions: http://rsx.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav Citations http://rsx.sagepub.com/cgi/content/refs/11/6/406 Downloaded from http://rsx.sagepub.com at Serials Records, University of Minnesota Libraries on December 2, 2008 Aromatase Inhibition Reduces the Dose of Gonadotropin Required for Controlled Ovarian Hyperstimulation Mohamed F. M. Mitwally, MD, and Robert F. Casper, MD OBJECTIVE: To compare the use of the aromatase inhibitor, letrozole, in conjunction with follicle- stimulating hormone (FSH) injection, and FSH alonefor controlled ovarian hyperstimulation (COH) in patients with polycystic ovarian syndrome (PCOS) or ovulatory infertility. METHODS: This nonrandomized study included two study groups: 26 patients with PCOS and 63 with ovulatory infertility (unexplained infertility [41 patients], malefactor infertility [17 patients], and endometriosis [5 patients]), who received letrozole in addition to FSH; and two control groups: 46 PCOS patients and 308 with ovulatory infertility (unexplained infertility [250patients], malefactor infertility [42 patients], and endometriosis [16 patients], who received FSH only.
    [Show full text]
  • Appendiks Til Marte Myhre Reigstad, Inger Kristin Larsen, Ritsa Storeng
    Appendiks til Marte Myhre Reigstad, Inger Kristin Larsen, Ritsa Storeng. Kreftrisiko hos mor og barn etter fertilitetsbehandling. Tidsskr Nor Legeforen 2018; 138. doi: 10.4045/tidsskr.17.1098. Dette appendikset er et tillegg til artikkelen og er ikke bearbeidet redaksjonelt. Ramme 1 Beskrivelse av søkestrengen Søket består av 3 deler; fertilitetsbehandling, risiko, kreft som er kombinert med AND. Det er søkt med kontrollerte emneord (MeSH eller EMTREE), ord i tittel/abstakt /forfatters nøkkelord, kombinert med OR, innenfor de tre delene. EMBASE: artificial insemination/ or embryo disposition/ or exp embryo transfer/ or fertilization in vitro/ or in vitro oocyte maturation/ or intracytoplasmic sperm injection/ or ovulation induction/ or in vitro oocyte maturation/ or intracytoplasmic sperm injection/ or ovulation induction/ or superovulation/ or chorionic gonadotropin/ or clomifene/ or clomifene citrate/ or corifollitropin alfa/ or follitropin/ or gonadotropin/ or human menopausal gonadotropin/ or recombinant chorionic gonadotropin/ or recombinant follitropin/ or recombinant follitropin plus recombinant luteinizing hormone/ or recombinant luteinizing hormone/ or urofollitropin/ or gonadorelin/ or (gonadotropin* or clomifene or clomiphene or corifollitropin* or follitropin* or recombinant luteinizing hormone or urofollitropin* or gonadorelin* or buserelin* or leuprolide or menotropin* or nafarelin* or (fertilization* adj3 vitro) or (fertilisation* adj3 vitro) or (fertilization* adj3 invitro) or (fertilisation* adj3 invitro) or ivf or intracytoplasmic
    [Show full text]
  • Pharmacy Prior Authorization Guideline
    Harvard Pilgrim Health Care – Pharmacy Prior Authorization Guideline Guideline Name Gonadotropins and Antigonadotropins: Bravelle (urofollitropin), Cetrotide (cetrorelix), chorionic gonadotropin, Ganirelix, Gonal-F (follitropin alfa), Follistim AQ (follitropin beta), Menopur (menotropin), Novarel (chorionic gonadotropin), Ovidrel (choriogonadotropin alfa), and Pregnyl (chorionic gonadotropin) 1 . Criteria Product Name: Bravelle, Cetrotide, generic chorionic gonadotropin, Ganirelix, Gonal-F, Gonal- F RFF, Menopur, Novarel, Ovidrel, Pregnyl Diagnosis Gonadotropin therapy for females with infertility** Approval Length As requested up to 7 Month(s)* Guideline Type Prior Authorization Approval Criteria 1 - Patient has been approved for infertility services through a Harvard Pilgrim Health Care (HPHC) medical authorization^ Notes ^ The approval duration for formulary infertility medications (authorized by HPHC Pharmacy Benefit) will be approved 1 month prior to the date of the medical infertility services authorization (authorized by HPHC Medical Benefit) plus an additional 6 months unless specified otherwise on PA request (for a total of up to 7 months). *For approvals: Please approve at GPI List Name HPHCMEDIVF. **Some plans EXCLUDE gonadotropin products for infertility and claims will reject as Plan Exclusion: Plan excludes meds for infertility. Product Name: Follistim AQ Diagnosis Gonadotropin therapy for females with infertility** Approval Length As requested up to 7 Month(s) Guideline Type Non-Formulary Approval Criteria 1 - Patient has
    [Show full text]
  • Gonadotropin‑Releasing Hormone Analogs: Understanding Advantages and Limitations
    Review Article Gonadotropin‑releasing hormone analogs: Understanding advantages and limitations ABSTRACT Pratap Kumar, Alok Sharma1 Pituitary stimulation with pulsatile gonadotropin‑releasing hormone (GnRH) analogs Department of Obstetrics and induces both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). Pituitary Gynecology, Kasturba Medical College, Manipal University, gonadotropin secretions are blocked upon desensitization when a continuous GnRH Manipal, Karnataka, stimulus is provided by means of an agonist or when the pituitary receptors are occupied 1Department of Obstetrician with a competitive antagonist. GnRH antagonists were not available originally; therefore, and Gynecologist, Deen Dayal prolonged daily injections of agonist with its desensitizing effect were used. Today, Upadhyaya Hospital, Shimla, Himachal Pradesh, India single‑ and multiple‑dose injectable antagonists are also available to block the LH surge and thus to cause desensitization. This review provides an overview of the use of GnRH analogs Address for correspondence: which is potent therapeutic agents that are considerably useful in a variety of clinical Dr. Pratap Kumar, indications from the past to the future with some limitations. These indications include Department of Obstetrics and Gynecology, Kasturba Medical management of endometriosis, uterine leiomyomas, hirsutism, dysfunctional uterine College, Manipal University, bleeding, premenstrual syndrome, assisted reproduction, and some hormone‑dependent Manipal ‑ 576 104, tumours, other than
    [Show full text]
  • Revision File
    King Saud University College of Medicine 2nd Year, Reproduction Block Revision File This work includes lectures from 2 to 10 and it Contains 72 MCQs .. Hope this work will help you to remember the important thing about each drug. Good Luck L2- Drugs Inducing ovulation Q1: an obese female patient come to the hospital and she is complaining from infertility with investigation we found high LH and blood glucose with low FSH and on ultrasound we found small cysts looks like necklace so we confirmed the diagnosis of Polycystic ovarian syndrome what are the drugs of choice in this case ? A) Clomiphene+ Pregnyl. B) Clomiphene+ Metformin. : C. : 4 C) Leuprolin+ Bromocreptine. Q D) Bromocreptine+ Menotropin. Q2: Which one of the following drug can be used in case of Female infertility diagnosed with breast cancer ? : B. B. : A) Clomiphene. 3 B) Bromocreptine C) Leuprolin. D) Tamoxifen. D. Q D. : 2 Q3:which one of these drugs can treat infertile woman with high level of prolactin hormone in her blood ? Q A) Tamoxifen. B) Bromocreptine. C) Leuprolin. B. B. : D) Clomiphene. 1 Q Q4:in case of Normogonadotrophic which one is the best choice ? A) Leuprolin. B) Metformin. C) Clomiphene. D) Bromocreptine. L2- Drugs Inducing ovulation Q5: A patient diagnosed with prostate cancer which one can be used in this case ? A) Continuous use of Leuprolin. B) Continuous use of GOSERELIN. C) Pulsatile use of Leuprolin. D) A+B. : D.: 8 Q6: Which one of the following sentence is correct about the administration of clomiphene ? A) Give 50 mg/d for 5 days from 5th day of the cycle to the 10th day.
    [Show full text]
  • Scientific Congress
    SCIENTIFIC CONGRESS ADVANCING REPRODUCTIVE MEDICINE BUILD HEALTHY FAMILIES OCTOBER 28 - NOVEMBER 1, 2017 INSIDE this program OPENING CEREMONY .......... 2 ASRM WELCOME. 3 COMMITTEES AND AWARDS ASRM SCIENTIFIC CONGRESS PLANNING COMMITTEES ........ 7 ASRM OFFICERS AND BOARD OF DIRECTORS .......... 7 ASRM COMMITTEES ............8,9 SOCIETY AWARDS ...........10-23 ASRM STAR AWARDS .........24-26 ASRM SERVICE MILESTONE AWARDS ......................26 DISCLOSURE STATEMENTS AND CONFLICT OF INTEREST POLICY .. 27 SCHEDULE-AT-A-GLANCE. .29-31 JOIN US FOR OUR DAILY SCHEDULE ...........32-40 CONTINUING EDUCATION/ Opening Ceremony CME SESSIONS CONTINUING MEDICAL EDUCATION / CONTINUING EDUCATION .....43-44 Monday, October 30th, 7:45 am – 8:45 am PRE-CONGRESS COURSES ...45-66 in the Henry B. Gonzalez Convention Center NEEDS ASSESSMENT AND Hemisfair Ballroom LEARNING OBJECTIVES. 67 ASRM 2017 CONGRESS GRID. 68 PLENARY SESSIONS .........69-74 Come hear ASRM President, Dr. Richard Paulson, discuss LECTURES .................75-77 the Society's accomplishments this year and plans for SYMPOSIA .................78-96 "Advancing Reproductive Medicine to Build Healthy Families." INTERACTIVE SESSIONS .....97-108 ADDITIONAL SESSIONS ....109-113 TRACKS .................114-126 Plenary 1 will immediately follow in the same room. SPEAKER INDEX ..........127-128 DISCLOSURES ............129-133 A complimentary continental breakfast will be available NON-CME EDUCATIONAL SESSIONS 7:00 am – 7:45 am TICKETED EVENTS .........135-138 in the ASRM 5K RUN INFORMATION .. 135 Hemisfair Ballroom Lobby EXPERT ENCOUNTERS ........ 136 ROUNDTABLE DISCUSSIONS 139-145 VIDEO SESSIONS ..........146-153 ABSTRACT REVIEW COMMITEES .............155-156 ORAL ABSTRACT PRESENTATIONS ..........157-192 POSTER ABSTRACT PRESENTATIONS ..........193-259 ABSTRACT TOPIC INDEX ...260-262 ABSTRACT AUTHOR INDEX .263-292 DISCLOSURES ............293-308 ASRM 2O17 SCIENTIFIC CONGRESS :: FINAL PROGRAM Congress attendees.
    [Show full text]
  • Assessment Report
    31 July 2013 EMA/CHMP/41467/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Ovaleap International non-proprietary name: follitropin alfa Procedure No. EMEA/H/C/002608 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union Table of contents 1. Background information on the procedure .............................................. 8 1.1. Submission of the dossier ...................................................................................... 8 1.2. Manufacturers ...................................................................................................... 9 1.3. Steps taken for the assessment of the product ......................................................... 9 2. Scientific discussion .............................................................................. 10 2.1. Introduction....................................................................................................... 10 2.2. Quality aspects .................................................................................................. 12 2.2.1. Introduction .................................................................................................... 12 2.2.2. Active Substance ............................................................................................
    [Show full text]
  • HUMAN MENOPAUSAL GONADOTROPINS (HMG) Policy Number: PHARMACY 288.3 T2 Effective Date: November 1, 2017
    UnitedHealthcare® Oxford Clinical Policy HUMAN MENOPAUSAL GONADOTROPINS (HMG) Policy Number: PHARMACY 288.3 T2 Effective Date: November 1, 2017 Table of Contents Page Related Policy INSTRUCTIONS FOR USE .......................................... 1 Acquired Rare Disease Drug Therapy Exception CONDITIONS OF COVERAGE ...................................... 1 Process BENEFIT CONSIDERATIONS ...................................... 2 Infertility Diagnosis and Treatment COVERAGE RATIONALE ............................................. 2 U.S. FOOD AND DRUG ADMINISTRATION .................... 4 APPLICABLE CODES ................................................. 5 CLINICAL EVIDENCE ................................................. 5 REFERENCES ........................................................... 8 POLICY HISTORY/REVISION INFORMATION ................ 10 INSTRUCTIONS FOR USE This Clinical Policy provides assistance in interpreting Oxford benefit plans. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members. Oxford reserves the right, in its sole discretion, to modify its policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice. The term Oxford includes Oxford Health Plans, LLC and all of its subsidiaries as appropriate for these policies. When deciding coverage, the member specific benefit plan document must be referenced. The terms of the member specific benefit plan document [e.g., Certificate of Coverage (COC), Schedule of Benefits (SOB), and/or Summary
    [Show full text]
  • Bilaga Till Rapport 1 (96) Endometrios – Diagnostik, Behandling Och Bemötande / Endometriosis – Diagnosis, Treatment and Patients’ Experiences, Rapport 277 (2018)
    Bilaga till rapport 1 (96) Endometrios – diagnostik, behandling och bemötande / Endometriosis – diagnosis, treatment and patients’ experiences, rapport 277 (2018) Bilaga 3 Exkluderade studier Appendix 3 Excluded studies Diagnostik Referens Exklusionsorsak Aboulghar MM, Hegazy M, Saber W, Hamed A, El Sheikhah A. Three- Fel frågeställning dimensional ultrasound versus office hysteroscopy in assessment of pain and bleeding with intrauterine contraceptive device. Middle East Fertil Soc J 2011;16:121-4. Acar S, Millar E, Mitkova M, Mitkov V. Value of ultrasound shear wave Fel studiedesign elastography in the diagnosis of adenomyosis. Ultrasound 2016;24:205-13. Adams F, Short J. Trans-vaginal ultrasound in diagnosing adenomyosis.Aust Fel studiedesign N Z J Obstet Gynaecol 2016;56:28. Ahmadi F, Haghighi H. Three-dimensional ultrasound manifestations of Fel studiedesign adenomyosis. Iran J Reprod Med 2013;11:847-8. Akturk E, Dede M, Yenen MC, Kocyigit YK, Ergun A. Comparison of nine Fel population morphological scoring systems to detect ovarian malignancy. Eur J Gynaecol Oncol 2015;36:304-8. Alcázar JL, Galan MJ, Mínguez JA, García-Manero M. Transvaginal color Fel population Doppler sonography versus sonohysterography in the diagnosis of endometrial polyps. J Ultrasound Med 2004;23:743-748. Andreotti RF, Fleischer AC. The sonographic diagnosis of adenomyosis. Ultrasound Q 2005;21:167-70. Ascher SM, Agrawal R, Bis KG, Brown ED, Maximovich A, Markham SM, Fel studiedesign et al. Endometriosis: appearance and detection with conventional and contrast-enhanced fat-suppressed spin-echo techniques. J Magn Reson Imaging 1995;5:251-7. Atri M, Reinhold C, Bret PM, Mehio AR, Chapman WB. Adenomyosis: US Fel studiedesign features with histologic correlation in an in-vitro study.
    [Show full text]
  • Efficacy, Efficiency and Effectiveness of Gonadotropin Therapy for Infertility Treatment
    REVIEW Efficacy, efficiency and effectiveness of gonadotropin therapy for infertility treatment Sandro C. EstevesI I ANDROFERT, Centro de Referência para Reprodução Humana, Av. Dr. Heitor Penteado, 1464, Campinas 13075-460, SP, Brazil. Gonadotropin therapy is an essential element in infertility treatments involving assisted reproductive technology. In recent years there have been outstanding advances in the development of new gonadotropins, particularly with the production of gonadotropins using biotechnological resources. Recombinant gonadotropins have higher specific activity compared with urinary counterparts, thus allowing subcutaneous administration of minimal amounts of glycoprotein. As a result, recombinant formulations have a better safety profile despite an overall similarity in terms of efficacy for pregnancy, as reported in many randomized controlled trials and meta-analyses. Gonadotropins stimulate the ovaries to develop follicles and oocytes, which are the raw material for fertilization and embryo production. The resulting embryos are transferred (fresh or frozen-thawed) to achieve pregnancy. The efficiency of a gonadotropin should therefore measured by the amount of drug used, the number of oocytes/embryos produced, and the number of pregnancies achieved by transferring fresh and/or frozen-thawed embryos to the uterus (cumulative pregnancy). Comparisons between different gonadotropin preparations should also take into account other important quality indicators in reproductive medicine, such as safety and patient-centeredeness.
    [Show full text]
  • Specialty Guideline Management
    Reference number C14414-A SPECIALTY GUIDELINE MANAGEMENT North Carolina State Health Plan: Fertility Agents PROGRAM RATIONALE Client Requested: The intent of the criteria is to ensure that patients follow selection elements established by North Carolina State Health Plan’s Commercial Prior Authorization Approval policy. PRIOR AUTHORIZATION CRITERIA1 • Coverage is provided for female infertility treatment and in males for non-infertility indications. • Coverage is NOT provided for patients using fertility medication in conjunction with any type of Artificial Reproductive Technology (ART) procedure. ART procedures include In Vitro Fertilization (IVF), Gamete Intrafallopian Transfer (GIFT), Zygote Intrafallopian Transfer (ZIFT), Intracytoplasmic Sperm Injection (ICSI) and Intrauterine (IUI) or Artificial Insemination. COVERED FERTILITY AGENTS* Medication Generic Name Covered Indications Gonadotropins Follicle Stimulating Hormone (FSH) Follistim AQ† follitropin beta . Ovulation induction . Hypogonadotropic hypogonadism in males Gonal-F/ follitropin alfa . Ovulation induction Gonal-F RFF Pen . Hypogonadotropic hypogonadism in males Human Chorionic Gonadotropin (hCG) Novarel†, Pregnyl†, chorionic gonadotropin . Ovulation induction hcG (generic)† . Selected cases of hypogonadotropic hypogonadism in males (i.e., hypogonadism secondary to a pituitary deficiency) . Prepubertal cryptorchidism Ovidrel choriogonadotropin alfa . Ovulation induction . Selected cases of hypogonadotropic hypogonadism in males (i.e., hypogonadism secondary to a pituitary
    [Show full text]